New Directions in the Genomics of Allogeneic Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 2, 2007, Pages 127-144

  Mullighan, Charles G ^a,b   Bardy, Peter G ^b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cytokine; Genomics; Hematopoietic; Interleukin; Mannose binding lectin; Natural killer cell; Pharmacogenomics; Polymorphism; Transplantation; Tumor necrosis factor

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA2 INTEGRIN; AZATHIOPRINE; BUSULFAN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD31 ANTIGEN; GAMMA INTERFERON; GLUTATHIONE TRANSFERASE; HLA ANTIGEN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MANNOSE BINDING LECTIN; MERCAPTOPURINE; METHOTREXATE; MINOR HISTOCOMPATIBILITY ANTIGEN; MYELOPEROXIDASE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; DRUG METABOLISM; DRUG TARGETING; GENETIC ANALYSIS; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GRAFT INFECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HIGH THROUGHPUT SCREENING; HLA MATCHING; HUMAN; IMMUNOGENETICS; MAJOR HISTOCOMPATIBILITY COMPLEX; MARKER GENE; METHODOLOGY; MORTALITY; MUCOSA INFLAMMATION; NATURAL KILLER CELL; PATHOGENESIS; PATIENT CARE; PHARMACOGENOMICS; PREDICTION; RELAPSE; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; VEIN OCCLUSION;

GENOMICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; KILLER CELLS, NATURAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 33846288929     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.018     Document Type: Review

References (180)

1. Loberiza F. The 2003 BMT summary slides with guide. IBMTR/ABMTR Newslett (2003) 7-10
2. Gratwohl A., Brand R., Frassoni F., et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 36 (2005) 757-769
3. Mielcarek M., Martin P.J., Leisenring W., et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 102 (2003) 756-762
4. Mickelson E.M., Petersdorf E., Anasetti C., Martin P., Woolfrey A., and Hansen J.A. HLA matching in hematopoietic cell transplantation. Hum Immunol 61 (2000) 92-100
5. Billingham R.E. The biology of graft-versus-host reactions. Harvey Lect 62 (1966) 21-78
6. Petersdorf E.W., and Malkki M. Human leukocyte antigen matching in unrelated donor hematopoietic cell transplantation. Semin Hematol 42 (2005) 76-84
7. Petersdorf E.W., Gooley T.A., Anasetti C., et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92 (1998) 3515-3520
8. Ferrara J.L., and Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 43 (2006) 3-10
9. Flomenberg N., Baxter-Lowe L.A., Confer D., et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104 (2004) 1923-1930
10. Petersdorf E.W., Anasetti C., Martin P.J., et al. Limits of HLA mismatching in unrelated hematopoietic cell transplantation. Blood 104 (2004) 2976-2980
11. Mullighan C.G., and Petersdorf E.W. Genomic polymorphism and allogeneic hematopoietic transplantation outcome. Biol Blood Marrow Transplant 12 (2006) 19-27
12. Goulmy E. Human minor histocompatibility antigens. Curr Opin Immunol 8 (1996) 75-81
13. Marijt W.A., Heemskerk M.H., Kloosterboer F.M., et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci USA 100 (2003) 2742-2747
14. Chao N.J. Minors come of age: minor histocompatibility antigens and graft-versus-host disease. Biol Blood Marrow Transplant 10 (2004) 215-223
15. Goulmy E. Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 67 (2006) 433-438
16. den Haan J.M., Meadows L.M., Wang W., et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 279 (1998) 1054-1057
17. Goulmy E., Schipper R., Pool J., et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334 (1996) 281-285
18. Tseng L.H., Lin M.T., Hansen J.A., et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 94 (1999) 2911-2914
19. Lin M.T., Gooley T., Hansen J.A., et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen-HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 98 (2001) 3172-3173
20. Balduini C.L., Frassoni F., Noris P., et al. Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. Br J Haematol 114 (2001) 951-953
21. Perez-Garcia A., De la Camara R., Torres A., Gonzalez M., Jimenez A., and Gallardo D. Minor histocompatibility antigen HA-8 mismatch and clinical outcome after HLA-identical sibling donor allogeneic stem cell transplantation. Haematologica 90 (2005) 1723-1724
22. Tait B.D., Maddison R., McCluskey J., et al. Clinical relevance of the minor histocompatibility antigen HA-1 in allogeneic bone marrow transplantation between HLA identical siblings. Transplant Proc 33 (2001) 1760-1761
23. Rocha V., Franco R.F., Porcher R., et al. Host defense and inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone marrow transplantation. Blood 100 (2002) 3908-3918
24. Kogler G., Middleton P.G., Wilke M., et al. Recipient cytokine genotypes for TNF-alpha and IL-10 and the minor histocompatibility antigens HY and CD31 codon 125 are not associated with occurrence or severity of acute GVHD in unrelated cord blood transplantation: a retrospective analysis. Transplantation 74 (2002) 1167-1175
25. Heinemann F.M., Ferencik S., Ottinger H.D., Beelen D.W., and Grosse-Wilde H. Impact of disparity of minor histocompatibility antigens HA-1, CD31, and CD49b in hematopoietic stem cell transplantation of patients with chronic myeloid leukemia with sibling and unrelated donors. Transplantation 77 (2004) 1103-1106
26. Behar E., Chao N.J., Hiraki D.D., et al. Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease. N Engl J Med 334 (1996) 286-291
27. Nichols W.C., Antin J.H., Lunetta K.L., et al. Polymorphism of adhesion molecule CD31 is not a significant risk factor for graft-versus-host disease. Blood 88 (1996) 4429-4434
28. Maruya E., Saji H., Seki S., et al. Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 92 (1998) 2169-2176
29. Cavanagh G., Chapman C.E., Carter V., Dickinson A.M., and Middleton P.G. Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. Transplantation 79 (2005) 602-605
30. Katagiri T., Shiobara S., Nakao S., et al. Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan. Bone Marrow Transplant 38 (2006) 681-686
31. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J 10 (2004) 1-7
32. Brickner A.G., Evans A.M., Mito J.K., et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 107 (2006) 3779-3786
33. Slager E.H., Honders M.W., van der Meijden E.D., et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 107 (2006) 4954-4960
34. Kircher B., Wolf M., Stevanovic S., et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J Immunother 27 (2004) 156-160
35. Dickinson A.M., Wang X.N., Sviland L., et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med 8 (2002) 410-414
36. Fontaine P., Roy-Proulx G., Knafo L., Baron C., Roy D.C., and Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 7 (2001) 789-794
37. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., and Ferrara J.L. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 90 (1997) 3204-3213
38. Cooke K.R., Olkiewicz K., Erickson N., and Ferrara J.L. The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 8 (2002) 441-448
39. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
40. Antin J.H., and Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 (1992) 2964-2968
41. Hattori K., Hirano T., Miyajima H., et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91 (1998) 4051-4055
42. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 102 (1998) 1882-1891
43. Allen M.J., Laederach A., Reilly P.J., and Mason R.J. Polysaccharide recognition by surfactant protein d: novel interactions of a C-type lectin with nonterminal glucosyl residues. Biochemistry 40 (2001) 7789-7798
44. Xun C.Q., Thompson J.S., Jennings C.D., Brown S.A., and Widmer M.B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83 (1994) 2360-2367
45. Holler E., Ertl B., Hintermeier-Knabe R., et al. Inflammatory reactions induced by pretransplant conditioning-an alternative target for modulation of acute GvHD and complications following allogeneic bone marrow transplantation?. Leuk Lymphoma 25 (1997) 217-224
46. Remberger M., Ringden O., and Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 15 (1995) 99-104
47. Imamura M., Hashino S., Kobayashi H., et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease. Bone Marrow Transplant 13 (1994) 745-751
48. Imamura M., Hashino S., Kobayashi S., et al. Hyperacute graft-versus-host disease accompanied by increased serum interleukin-6 levels. Int J Hematol 60 (1994) 85-89
49. Imamura M., Tanaka J., Hashino S., et al. Cytokines involved in graft-versus-host disease. Hokkaido Igaku Zasshi 69 (1994) 1348-1353
50. Takatsuka H., Takemoto Y., Okada M., et al. Changes of cytokines during the course of graft-versus-host disease following bone marrow transplantation: a case report. Cytokine 12 (2000) 1225-1227
51. Holler E., Kolb H.J., Moller A., et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 75 (1990) 1011-1016
52. Holler E., Kolb H.J., Hintermeier-Knabe R., et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 25 (1993) 1234-1236
53. Kayaba H., Hirokawa M., Watanabe A., et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol 106 (2000) S40-S44
54. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 28 (2001) 935-940
55. Remberger M., Jaksch M., Uzunel M., and Mattsson J. Serum levels of cytokines correlate to donor chimerism and acute graft-vs.-host disease after haematopoietic stem cell transplantation. Eur J Haematol 70 (2003) 384-391
56. Visentainer J.E., Lieber S.R., Persoli L.B., et al. Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol 31 (2003) 1044-1050
57. Miyamoto T., Akashi K., Hayashi S., et al. Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease. Bone Marrow Transplant 17 (1996) 185-190
58. Kami M., Matsumura T., Tanaka Y., et al. Serum levels of soluble interleukin-2 receptor after bone marrow transplantation: a true marker of acute graft-versus-host disease. Leuk Lymphoma 38 (2000) 533-540
59. Nakamura H., Komatsu K., Ayaki M., et al. Serum levels of soluble IL-2 receptor, IL-12, IL-18, and IFN-gamma in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation. J Allergy Clin Immunol 106 (2000) S45-S50
60. Niederwieser D., Herold M., Woloszczuk W., et al. Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation 50 (1990) 620-625
61. Symington F.W., Symington B.E., Liu P.Y., Viguet H., Santhanam U., and Sehgal P.B. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 54 (1992) 457-462
62. Abdallah A.N., Boiron J.M., Attia Y., Cassaigne A., Reiffers J., and Iron A. Plasma cytokines in graft vs host disease and complications following bone marrow transplantation. Hematol Cell Ther 39 (1997) 27-32
63. Schots R., Kaufman L., Van Riet I., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 17 (2003) 1150-1156
64. Holler E. Cytokines, viruses, and graft-versus-host disease. Curr Opin Hematol 9 (2002) 479-484
65. Nikolic B., Lee S., Bronson R.T., Grusby M.J., and Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest 105 (2000) 1289-1298
66. Mohty M., Blaise D., Faucher C., et al. Inflammatory cytokines and acute graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 106 (2005) 4407-4411
67. Ueno Y., Ishii M., Yahagi K., et al. Fas-mediated cholangiopathy in the murine model of graft versus host disease. Hepatology 31 (2000) 966-974
68. Middleton P.G., Taylor P.R., Jackson G., Proctor S.J., and Dickinson A.M. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92 (1998) 3943-3948
69. Cavet J., Middleton P.G., Segall M., Noreen H., Davies S.M., and Dickinson A.M. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 94 (1999) 3941-3946
70. Takahashi H., Furukawa T., Hashimoto S., et al. Contribution of TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 26 (2000) 1317-1323
71. Cavet J., Dickinson A.M., Norden J., Taylor P.R., Jackson G.H., and Middleton P.G. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Blood 98 (2001) 1594-1600
72. Cullup H., Dickinson A.M., Jackson G.H., Taylor P.R., Cavet J., and Middleton P.G. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br J Haematol 113 (2001) 807-813
73. Lorenz E., Schwartz D.A., Martin P.J., et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7 (2001) 384-387
74. Socie G., Loiseau P., Tamouza R., et al. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation 72 (2001) 699-706
75. Tambur A.R., Yaniv I., Stein J., et al. Cytokine gene polymorphism in patients with graft-versus-host disease. Transplant Proc 33 (2001) 502-503
76. Ishikawa Y., Kashiwase K., Akaza T., et al. Polymorphisms in TNFA and TNFR2 affect outcome of unrelated bone marrow transplantation. Bone Marrow Transplant 29 (2002) 569-575
77. Middleton P.G., Cullup H., Dickinson A.M., et al. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation. Bone Marrow Transplant 30 (2002) 223-228
78. Mullighan C.G., Heatley S., Doherty K., et al. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 99 (2002) 3524-3529
79. Nordlander A., Uzunel M., Mattsson J., and Remberger M. The TNFd4 allele is correlated to moderate-to-severe acute graft-versus-host disease after allogeneic stem cell transplantation. Br J Haematol 119 (2002) 1133-1136
80. Wang J.B., Ren H.Y., Li D., Sun Q., and Lu D.P. Frequency of donor TNF-alpha gene polymorphism in patients with graft versus host disease following hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10 (2002) 133-137
81. Bogunia-Kubik K., Polak M., and Lange A. TNF polymorphisms are associated with toxic but not with aGVHD complications in the recipients of allogeneic sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 617-622
82. Cullup H., Dickinson A.M., Cavet J., Jackson G.H., and Middleton P.G. Polymorphisms of interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Br J Haematol 122 (2003) 778-787
83. Lin M.T., Storer B., Martin P.J., et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 349 (2003) 2201-2210
84. MacMillan M.L., Radloff G.A., DeFor T.E., Weisdorf D.J., and Davies S.M. Interleukin-1 genotype and outcome of unrelated donor bone marrow transplantation. Br J Haematol 121 (2003) 597-604
85. Middleton P.G., Norden J., Cullup H., et al. Oestrogen receptor alpha gene polymorphism associates with occurrence of graft-versus-host disease and reduced survival in HLA-matched sib-allo BMT. Bone Marrow Transplant 32 (2003) 41-47
86. Stark G.L., Dickinson A.M., Jackson G.H., Taylor P.R., Proctor S.J., and Middleton P.G. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 76 (2003) 1742-1749
87. Cardoso S.M., DeFor T.E., Tilley L.A., Bidwell J.L., Weisdorf D.J., and MacMillan M.L. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. Br J Haematol 126 (2004) 704-710
88. Holler E., Rogler G., Herfarth H., et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104 (2004) 889-894
89. Keen L.J., DeFor T.E., Bidwell J.L., Davies S.M., Bradley B.A., and Hows J.M. Interleukin-10 and tumor necrosis factor alpha region haplotypes predict transplant-related mortality after unrelated donor stem cell transplantation. Blood 103 (2004) 3599-3602
90. Mullighan C., Heatley S., Doherty K., et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation 77 (2004) 587-596
91. Mlynarczewska A., Wysoczanska B., Karabon L., Bogunia-Kubik K., and Lange A. Lack of IFN-gamma 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 34 (2004) 339-344
92. Pihusch M., Lohse P., Reitberger J., et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 911-918
93. Shaw B.E., Maldonado H., Madrigal J.A., et al. Polymorphisms in the TNFA gene promoter region show evidence of strong linkage disequilibrium with HLA and are associated with delayed neutrophil engraftment in unrelated donor hematopoietic stem cell transplantation. Tissue Antigens 63 (2004) 401-411
94. Srivastava A., Poonkuzhali B., Shaji R.V., et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104 (2004) 1574-1577
95. Bogunia-Kubik K., Mlynarczewska A., Wysoczanska B., and Lange A. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 90 (2005) 425-456
96. Bogunia-Kubik K., and Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation 79 (2005) 815-820
97. Bogunia-Kubik K., Mlynarczewska A., Jaskula E., and Lange A. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 132 (2006) 326-332
98. Karabon L., Wysoczanska B., Bogunia-Kubik K., Suchnicki K., and Lange A. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Hum Immunol 66 (2005) 700-710
99. Kim D.H., Lee N.Y., Sohn S.K., et al. IL-10 promoter gene polymorphism associated with the occurrence of chronic GVHD and its clinical course during systemic immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell transplantation. Transplantation 79 (2005) 1615-1622
100. Lin M.T., Storer B., Martin P.J., et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 106 (2005) 3995-4001
101. Onizuka M., Kasai M., Oba T., et al. Increased frequency of the angiotensin-converting enzyme gene D-allele is associated with noninfectious pulmonary dysfunction following allogeneic stem cell transplant. Bone Marrow Transplant 36 (2005) 617-620
102. Seo K.W., Kim D.H., Sohn S.K., et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 36 (2005) 1089-1095
103. Laguila Visentainer J.E., Lieber S.R., Lopes Persoli L.B., et al. Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine 32 (2005) 171-177
104. Chien J.W., Zhao L.P., Hansen J.A., Fan W.H., Parimon T., and Clark J.G. Genetic variation in bactericidal/permeability-increasing protein influences the risk of developing rapid airflow decline after hematopoietic cell transplantation. Blood 107 (2006) 2200-2207
105. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 (2006) 4189-4193
106. Shamim Z., Ryder L.P., Heilmann C., et al. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant 37 (2006) 485-491
107. Terakura S., Murata M., Nishida T., et al. Increased risk for treatment-related mortality after bone marrow transplantation in GSTM1-positive recipients. Bone Marrow Transplant 37 (2006) 381-386
108. MacMillan M.L., Radloff G.A., Kiffmeyer W.R., DeFor T.E., Weisdorf D.J., and Davies S.M. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation 76 (2003) 1758-1762
109. Granell M., Urbano-Ispizua A., Arostegui J.I., et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica 91 (2006) 1372-1376
110. Rozman P., Karas M., Kosir A., et al. Are human platelet alloantigens (HPA) minor transplantation antigens in clinical bone marrow transplantation?. Bone Marrow Transplant 31 (2003) 497-506
111. Bettens F., Passweg J., Gratwohl A., et al. Association of TNFd and IL-10 polymorphisms with mortality in unrelated hematopoietic stem cell transplantation. Transplantation 81 (2006) 1261-1267
112. Hajeer A.H., and Hutchinson I.V. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 62 (2001) 1191-1199
113. Low A.S., Azmy I., Sharaf N., Cannings C., and Wilson A.G. Association between two tumour necrosis factor intronic polymorphisms and HLA alleles. Eur J Immunogenet 29 (2002) 31-34
114. Spink C.F., Keen L.J., Mensah F.K., Law G.R., Bidwell J.L., and Morgan G.J. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 133 (2006) 293-300
115. Turner D.M., Williams D.M., Sankaran D., Lazarus M., Sinnott P.J., and Hutchinson I.V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24 (1997) 1-8
116. Crawley E., Kay R., Sillibourne J., Patel P., Hutchinson I., and Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42 (1999) 1101-1108
117. Suarez A., Castro P., Alonso R., Mozo L., and Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 75 (2003) 711-717
118. Pawlik A., Baskiewicz-Masiuk M., Machalinski B., and Gawronska-Szklarz B. Association of cytokine gene polymorphisms and the release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Int Immunopharmacol 6 (2006) 351-357
119. Mullally A., and Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood (2006) doi:10.1182/blood-2006-06-030858
120. Dickinson A.M., and Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 17 (2005) 517-525
121. Dickinson A.M., and Middleton P.G. Beyond the HLA typing age: genetic polymorphisms predicting transplant outcome. Blood Rev 19 (2005) 333-340
122. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
123. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
124. Mullighan C.G., and Bardy P.G. Mannose-binding lectin and infection following allogeneic hemopoietic stem cell transplantation. Leuk Lymphoma 45 (2004) 247-256
125. Worthley D.L., Bardy P.G., and Mullighan C.G. Mannose-binding lectin: biology and clinical implications. Intern Med J 35 (2005) 548-555
126. Minchinton R.M., Dean M.M., Clark T.R., Heatley S., and Mullighan C.G. Analysis of the relationship between mannose-binding lectin (MBL) genotype, MBL levels and function in an Australian blood donor population. Scand J Immunol 56 (2002) 630-641
127. Horiuchi T., Gondo H., Miyagawa H., et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun 6 (2005) 162-166
128. Molle I., Peterslund N.A., Thiel S., and Steffensen R. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant 38 (2006) 555-560
129. Granell M., Urbano-Ispizua A., Lozano F., et al. Donor's mannan-binding lectin (MBL) gene polymorphism is associated with invasive fungal infection following allogeneic stem cell transplantation. Blood 104 (2004) 2220
130. Kesh S., Mensah N.Y., Peterlongo P., et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 1062 (2005) 95-103
131. Ulrich C.M., Robien K., and McLeod H.L. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3 (2003) 912-920
132. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu Rev Med 57 (2006) 119-137
133. Bornhauser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
134. Bolinger A.M., Zangwill A.B., Slattery J.T., et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 28 (2001) 1013-1018
135. Demirer T., Buckner C.D., Appelbaum F.R., et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 17 (1996) 491-495
136. Pui C.H., Relling M.V., and Evans W.E. Role of pharmacogenomics and pharmacodynamics in the treatment of acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15 (2002) 741-756
137. Frosst P., Blom H.J., Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
138. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
139. Ulrich C.M., Yasui Y., Storb R., et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 (2001) 231-234
140. Robien K., Schubert M.M., Bruemmer B., Lloid M.E., Potter J.D., and Ulrich C.M. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol 22 (2004) 1268-1275
141. Robien K., Ulrich C.M., Bigler J., et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res 10 (2004) 7592-7598
142. Robien K., Schubert M.M., Chay T., et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 37 (2006) 799-800
143. Kalayoglu-Besisik S., Caliskan Y., Sargin D., Gurses N., and Ozbek U. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation 76 (2003) 1775-1777
144. Murphy N., Diviney M., Szer J., et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 37 (2006) 773-779
145. Robien K., Bigler J., Yasui Y., et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant 12 (2006) 973-980
146. Farag S.S., Fehniger T.A., Ruggeri L., Velardi A., and Caligiuri M.A. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100 (2002) 1935-1947
147. Shilling H.G., McQueen K.L., Cheng N.W., Shizuru J.A., Negrin R.S., and Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101 (2003) 3730-3740
148. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
149. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102 (2003) 814-819
150. Davies S.M., Ruggieri L., DeFor T., et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 100 (2002) 3825-3827
151. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 63 (2004) 204-211
152. Bornhauser M., Schwerdtfeger R., Martin H., Frank K.H., Theuser C., and Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 103 (2004) 2860-2862
153. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 23 (2005) 3447-3454
154. Schaffer M., Malmberg K.J., Ringden O., Ljunggren H.G., and Remberger M. Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. Transplantation 78 (2004) 1081-1085
155. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 106 (2005) 4370-4376
156. Hsu K.C., Chida S., Geraghty D.E., and Dupont B. The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism. Immunol Rev 190 (2002) 40-52
157. Cook M.A., Moss P.A., and Briggs D.C. The distribution of 13 killer-cell immunoglobulin-like receptor loci in UK blood donors from three ethnic groups. Eur J Immunogenet 30 (2003) 213-221
158. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172 (2004) 644-650
159. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105 (2005) 4878-4884
160. Hsu K.C., Gooley T., Malkki M., et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 12 (2006) 828-836
161. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 103 (2004) 1521-1526
162. Chen C., Busson M., Rocha V., et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 38 (2006) 437-444
163. Cook M., Briggs D., Craddock C., et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 107 (2006) 1230-1232
164. Farag S.S., Bacigalupo A., Eapen M., et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 12 (2006) 876-884
165. Dickinson A.M. Biobanks and registries for HSCT research: potential for future individualized medicine. Int J Immunogenet 33 (2006) 153-154
166. Bidwell J., Keen L., Gallagher G., et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2 (2001) 61-70
167. Kaijzel E.L., Bayley J.P., van Krugten M.V., et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2 (2001) 135-144
168. Turner D.M., Grant S.C., Lamb W.R., et al. A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation 60 (1995) 1113-1117
169. 14th International HLA and Immunogenetics Workshop. Available at: http://www.microbiol.unimelb.edu.au/14ihiws//. Accessed September 12, 2006.
170. International HapMap Consortium. A haplotype map of the human genome. Nature 437 (2005) 1299-1320
171. Fan J.B., Chee M.S., and Gunderson K.L. Highly parallel genomic assays. Nat Rev Genet 7 (2006) 632-644
172. Affymetrix Microarray Bulletin; 2005. Available at: http://microarraybulletin.com/community/wp-content/uploads/2006/04/AMB_Ogawa_v1iss1.pdf. Accessed September 8, 2006.
173. Conrad D.F., Andrews T.D., Carter N.P., Hurles M.E., and Pritchard J.K. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 38 (2006) 75-81
174. Da Costa L., Charron D., and Loiseau P. Does the adhesion molecule CD31 act as a minor histocompatibility antigen?. Blood 90 (1997) 1332
175. Juji T., Watanabe Y., Ishikawa Y., et al. Human platelet alloantigen (HPA)-5a/b mismatch decreases disease-free survival in unrelated bone marrow transplantation. Tissue Antigens 54 (1999) 229-234
176. Akatsuka Y., Warren E.H., Gooley T.A., et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 123 (2003) 671-675
177. Nesci S., Buffi O., Iliescu A., Andreani M., and Lucarelli G. Recipient mHag-HA1 disparity and aGVHD in thalassemic-transplanted patients. Bone Marrow Transplant 31 (2003) 575-578
178. Nishida T., Akatsuka Y., Morishima Y., et al. Clinical relevance of a newly identified HLA-A24-restricted minor histocompatibility antigen epitope derived from BCL2A1, ACC-1, in patients receiving HLA genotypically matched unrelated bone marrow transplant. Br J Haematol 124 (2004) 629-635
179. Grumet F.C., Hiraki D.D., Brown B.W.M., et al. CD31 mismatching affects marrow transplantation outcome. Biol Blood Marrow Transplant 7 9 (2001) 503-512
180. Gallardo D., Arostegui J.I., Balas A., et al. Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donar transplantation. Br J Haematol 114 (2001) 931-936